InvidiCONCT06251518
Investigating the Effectiveness of Vimida
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 25 words Show 5 more changesShow less
- Trial completed
- Final enrollment: 176 participants (planned 160)
- Primary completion date changed from estimate of Sep 2025 to Sep 4, 2025
- Study completion date changed from estimate of Dec 2025 to Dec 1, 2025
- Secondary endpoints: details revised at 5 of 5 entries
- Notable Start date: Jul 8, 2024 to Feb 13, 2025
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Minor Primary completion date: Jul 8, 2025 to Sep 2025
- Study completion date: Jul 8, 2025 to Dec 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Primary and study completion dates: Jul 1, 2025 to Jul 8, 2025
- Start date changed from estimate of Jul 1, 2024 to Jul 8, 2024
- Notable Start date: Apr 15, 2024 to Jul 1, 2024
- Primary and study completion dates: Apr 15, 2025 to Jul 1, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (5)
Arms and interventions
Participants allocated to the intervention group received access to vimida in addition to treatment as usual (TAU). vimida is a digital health application designed for individuals with post-Covid conditions who suffer from fatigue, accessible through a web browser. The application focuses on treatment methods derived from cognitive behavioral therapy (CBT). Topics addressed by vimida are psychoeducation, activity and recovery, attention, stress management, sleep management, cognitive restructuring, and social resources. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivational text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 180 days.
Participants allocated to the control group received access to treatment as usual (TAU).
Behavioral: vimida
Sites
1 site in 1 country
- GAIAHamburg, Germany